AstraZeneca PLC's desire to become a clinical as well as a commercial powerhouse in China has led to the company setting up a drug development joint venture with a local private equity fund with the ultimate goal of getting medicines to market quicker.
The new entity, called Dizal Pharmaceutical, will be owned equally with the Chinese Future Industry Investment Fund (FIIF), which is...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

